| 产品描述: | JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation |
| 靶点: |
human complement C3a receptor |
| 体外研究: |
JR14a (0.1 nM-100 μM) inhibits C3a-induced intracellular Ca2+ release in human monocyte-derived macrophages, with an IC50 of 10 nM. JR14a (0.1 nM-100 μM) is metabolically stable to exposure over 1 h to rat liver microsomes. JR14a (0.1 nM-100 μM) inhibits C3a-induced β-hexosaminidase secretion in human LAD2 mast cells, with an IC50 of 8 nM. |
| 体内研究: |
JR14a (10 mg/kg; p.o. 2 h prior) 在炎症和水肿的急性大鼠爪模型中注射激动剂后 30 分钟,爪肿胀比对照减少 65%。 JR14a (1 mg/kg;iv) 在大鼠中表现出消除半衰期 (191 分钟)、清除率 (4.4 mL/min/kg) 和 AUC (3795 ng h/mL)。 JR14a (10 mg/kg;po) 在大鼠中表现出 Cmax (88 ng/mL)、Tmax (300 min) 和 AUC (478 ng h/mL)。 Animal Model:Male Wister rats (8 weeks, 250-300 g) were injected with BR103 Dosage:10 mg/kg Administration:P.o. 2 h prior to agonist challenge Result:Inhibited C3aR-mediated inflammation. Animal Model:Male Wister rats (8 weeks, 250-300 g) Dosage:1 mg/kg for i.v.; 10 mg/kg for oral (Pharmacokinetic Analysis) Administration:Intravenous administration and oral administration Result:I.v.: t1/2=191 min, clearance=4.4 mL/min/kg, AUC=3795 ng•h/mL.P.o.: Cmax=88 ng/mL, Tmax=300 min, AUC=478 ng•h/mL. |
| 参考文献: |
1. Rowley JA, et, al. Potent Thiophene Antagonists of Human Complement C3a Receptor with Anti-Inflammatory Activity. J Med Chem. 2020 Jan 23;63(2):529-541. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.875 ml |
9.373 ml |
18.745 ml |
| 5 mM |
0.375 ml |
1.875 ml |
3.749 ml |
| 10 mM |
0.187 ml |
0.937 ml |
1.875 ml |
| 50 mM |
0.037 ml |
0.187 ml |
0.375 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |